Arix Bioscience

Arix Bioscience is a global healthcare and life science company that drives value in private and public companies through operational and strategic direction as well as patient capital Their extensive experience in academic science, clinical and commercial strategy, company operations, mergers and acquisitions, venture capital and corporate finance puts them in an especially strong position to build and support a wide range of businesses and technologies. Arix Bioscience has privileged agreements with leading universities in the UK, Europe and Australia, providing direct access to innovative new technologies. They also have access to a broad range of research projects from US academic institutions.
FB

Felix Breyer

Associate

Robert Lyne

CEO and General Counsel

AM

Arthur M. Pappas

Independent Non-Executive Director

CP

Charlotte Parry

Head of Investor Relations

24 past transactions

Autolus Therapeutics plc

Series B in 2016
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of hematological malignancies and solid tumors. The company is developing AUTO1 and AUTO3 for B cell malignancies; AUTO2 for the treatment of multiple myeloma; AUTO4 and AUTO 5 for T cell lymphoma; and AUTO6 and AUTO7 to treat solid tumors. The company was founded in 2014 and is headquartered in London, the United Kingdom.

VelosBio, Inc.

Series A in 2018
VelosBio, Inc., a biopharmaceutical company, develops novel antibody-drug conjugates (ADCs) to treat hematological cancers and solid tumors. The company develops cancer therapies targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1). Its portfolio includes VLS-101, a ROR1-directed antibody-drug conjugate for patients with hematologic and solid tumor malignancies. The company was incorporated in 2017 and is headquartered in San Diego, California. As of December 18, 2020, VelosBio, Inc. operates as a subsidiary of Merck & Co., Inc.

Disc Medicine, Inc.

Series B in 2021
Disc Medicine is led by an experienced team of scientists and industry experts, and supported by a panel of advisors with a strong track record of discovering and developing new and innovative therapies. Disc Medicine was founded by Atlas Venture and Brian MacDonald, with Novo Ventures and Access Biotechnology joining as additional investors.
Amplyx Pharmaceuticals is a pre-clinical stage company focusing on the development of small molecule drugs with enhanced efficacy and lower toxicity. Amplyx employs a platform approach to improve small molecule drugs by the addition of a second small molecule to an existing drug. The company develops innovative therapies for debilitating and life-threatening diseases that affect people with compromised immune systems. Amplyx Pharmaceuticals was founded in 2006 and is headquartered in San Diego, California.

Aura Biosciences, Inc.

Venture Round in 2021
Aura Biosciences, Inc., a biotechnology company, develops a class of therapies to target and destroy cancer cells using viral nano-particle conjugates. The company develops AU-011 that includes viral nanoparticles, modeled on the human papillomavirus (HPV), conjugated to infrared-activated small molecules. The company’s AU-011 is used for the treatment of ocular (uveal) melanoma, which is a primary cancer of the eye. The company was incorporated in 2009 and is based in Cambridge, Massachusetts.

Atox Bio Inc.

Series F in 2017
Atox Bio is a biotechnology company that specializes in infectious diseases, immunomodulators, and critical care.It focuses on novel modulators of the immune response that target key multiple and interrelated pathways of both the adaptive and innate immune response that play critical roles in infectious and inflammatory diseases as well as ischemia/reperfusion injuries. The company was founded in 2003 and headquartered in HaMerkaz, Israel.

Depixus SAS

Series A in 2021
Depixus SAS, a biotechnology company, develops a technology platform for the extraction of genetic and epigenetic information from single DNA and RNA molecules. It offers SIngle-molecule Magnetic DEtection and Quantification technology platform, a DNA/RNA interrogation technology that enables the analysis of genomes and epigenetic modifications. The company serves life-science and medical industries. Depixus SAS was incorporated in 2012 and is based in Paris, France.

Artios Pharma

Series A in 2016
Artios Pharma Limited, a biotechnology company, focuses on developing cancer treatments that target DNA damage response (DDR) pathways to selectively kill cancer cells. Its product pipeline includes DNA polymerase theta (Polθ), which is involved in multiple processes associated with DNA repair; an in-licensed program that targets a protein that has been identified as a novel DNA damage response target; and a novel cancer treatment targeting DNA nucleases involved in the DDR. The company was incorporated in 2015 and is headquartered in Cambridge, United Kingdom.

Autolus Therapeutics plc

Series C in 2017
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of hematological malignancies and solid tumors. The company is developing AUTO1 and AUTO3 for B cell malignancies; AUTO2 for the treatment of multiple myeloma; AUTO4 and AUTO 5 for T cell lymphoma; and AUTO6 and AUTO7 to treat solid tumors. The company was founded in 2014 and is headquartered in London, the United Kingdom.

Mitoconix Bio

Series A in 2017
Mitoconix Bio Ltd develops a novel strategy to improve mitochondrial health as a disease modifying therapeutic for neurodegenerative diseases. The company was founded in 2016 and is based in Jerusalem, Israel.

Quench Bio, Inc.

Seed Round in 2018
Quench Bio is a developer of gasdermin biology drugs designed to treat severe inflammatory diseases.The company leverages insights into gasdermin biology and innate immunity to develop medicines with lead compounds that target and inhibit the pore-forming protein that mediates the release of inflammatory cytokines, alarmins, DNA and NETs, enabling patients to get relief from inflammatory diseases.
Amplyx Pharmaceuticals is a pre-clinical stage company focusing on the development of small molecule drugs with enhanced efficacy and lower toxicity. Amplyx employs a platform approach to improve small molecule drugs by the addition of a second small molecule to an existing drug. The company develops innovative therapies for debilitating and life-threatening diseases that affect people with compromised immune systems. Amplyx Pharmaceuticals was founded in 2006 and is headquartered in San Diego, California.

Harpoon Therapeutics

Series B in 2017
Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC), platform, Harpoon is developing a pipeline of novel T cell engagers, or TriTACs, initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon's first drug candidate, HPN424, is currently in Phase 1 clinical trial as a treatment for prostate cancer.

Aura Biosciences, Inc.

Series C in 2017
Aura Biosciences, Inc., a biotechnology company, develops a class of therapies to target and destroy cancer cells using viral nano-particle conjugates. The company develops AU-011 that includes viral nanoparticles, modeled on the human papillomavirus (HPV), conjugated to infrared-activated small molecules. The company’s AU-011 is used for the treatment of ocular (uveal) melanoma, which is a primary cancer of the eye. The company was incorporated in 2009 and is based in Cambridge, Massachusetts.

LogicBio Therapeutics

Series B in 2017
LogicBio develops gene therapy vectors for previously incurable genetic and infectious diseases, including: hemophilia, HIV/AIDS and methylmalonic acidemia (MMA). Our proprietary technology based on the non-pathogenic Adeno-Associated Viral (AAV) vector offers superior efficiency and safety compared to all competitors on the market, and is uniquely suited for the treatment of children as well as adults.

Quench Bio, Inc.

Series A in 2020
Quench Bio is a developer of gasdermin biology drugs designed to treat severe inflammatory diseases.The company leverages insights into gasdermin biology and innate immunity to develop medicines with lead compounds that target and inhibit the pore-forming protein that mediates the release of inflammatory cytokines, alarmins, DNA and NETs, enabling patients to get relief from inflammatory diseases.

IMARA Inc.

Series B in 2019
Imara, Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. It develops IMR-687, which is an oral, once-a-day therapeutic for the treatment of sickle cell disease and b-thalassemia. The company was founded in 2016 and is headquartered in Boston, Massachusetts.

Harpoon Therapeutics

Series C in 2018
Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC), platform, Harpoon is developing a pipeline of novel T cell engagers, or TriTACs, initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon's first drug candidate, HPN424, is currently in Phase 1 clinical trial as a treatment for prostate cancer.

Artios Pharma

Series B in 2018
Artios Pharma Limited, a biotechnology company, focuses on developing cancer treatments that target DNA damage response (DDR) pathways to selectively kill cancer cells. Its product pipeline includes DNA polymerase theta (Polθ), which is involved in multiple processes associated with DNA repair; an in-licensed program that targets a protein that has been identified as a novel DNA damage response target; and a novel cancer treatment targeting DNA nucleases involved in the DDR. The company was incorporated in 2015 and is headquartered in Cambridge, United Kingdom.

GenSight Biologics

Post in 2020
GenSight Biologics develops gene therapy-based treatments for retinal degenerative diseases. GenSight Biologics is a privately owned biopharmaceutical company, dedicated to the development and commercialization of gene therapy-based treatments of retinal degenerative diseases. Based on recent results obtained by the teams of its scientific founders, the company develops innovative approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from very low vision or blindness.

Stipe Therapeutics

Series A in 2019
STipe Therapeutics focuses on harnessing the innate immune system to battle cancer. The company has developed first-in-class drugs targeting intracellular protein-protein interactions of the STING Pathway; a major driver of innate immunity, and regulator of tumorigenesis and autoimmune disorders. The company has identified and validated compounds that sensitizes the STING pathway and by this modulates the tumor microenvironment to support a potent anti-tumoral response.

PreciThera

Series A in 2017
PreciThera, Inc. is a biotechnology company committed to the development of therapies for rare bone diseases using the combined application of computational technology and a deep understanding of disease pathology. The company focuses on heterogeneous genetic disorders that primarily manifest in bone dysfunction. In depth understanding of disease mechanism will allow PreciThera’s targeted strategies to meaningfully impact both the skeletal symptoms as well as the extraskeletal issues found in these patients.

Iterum Therapeutics plc

Series B in 2017
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a novel penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was founded in 2015 and is headquartered in Dublin, Ireland.